These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 12567303)
1. Nicotinamide: an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus. Murray MF Clin Infect Dis; 2003 Feb; 36(4):453-60. PubMed ID: 12567303 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. HIV infection and multidrug-resistant tuberculosis: the perfect storm. Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830 [TBL] [Abstract][Full Text] [Related]
4. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Canueto-Quintero J; Caballero-Granado FJ; Herrero-Romero M; Domínguez-Castellano A; Martín-Rico P; Verdú EV; Santamaría DS; Cerquera RC; Torres-Tortosa M; Clin Infect Dis; 2003 Aug; 37(4):584-90. PubMed ID: 12905144 [TBL] [Abstract][Full Text] [Related]
5. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Williams BG; Dye C Science; 2003 Sep; 301(5639):1535-7. PubMed ID: 12920302 [TBL] [Abstract][Full Text] [Related]
6. [Tuberculosis and HIV infection--main diagnostic and therapeutic problems]. Dabrowska MM; Pogorzelska J; Parfieniuk A; Siwak E; Wiercińska-Drapało A Pol Merkur Lekarski; 2007 Sep; 23(135):212-4. PubMed ID: 18080698 [TBL] [Abstract][Full Text] [Related]
7. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
8. Managing TB in the 21st century: existing and novel drug therapies. Guy ES; Mallampalli A Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385 [TBL] [Abstract][Full Text] [Related]
9. 2-(4-Pyridyl)-delta 2-1,3,4-oxadiazolines from isonicotinoylhydrazones and diazomethane as potential antimycobacterial and anti-HIV agents. V. Vigorita MG; Ottanà R; Zappalà C; Maccari R; Pizzimenti FC; Gabbrielli G Farmaco; 1995 Nov; 50(11):783-6. PubMed ID: 8593176 [TBL] [Abstract][Full Text] [Related]
10. Attenuation of HIV-1 infection by other microbial agents. Kannangara S; DeSimone JA; Pomerantz RJ J Infect Dis; 2005 Sep; 192(6):1003-9. PubMed ID: 16107952 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Fattorini L; Gennaro R; Zanetti M; Tan D; Brunori L; Giannoni F; Pardini M; Orefici G Peptides; 2004 Jul; 25(7):1075-7. PubMed ID: 15245864 [TBL] [Abstract][Full Text] [Related]
12. LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. Haraguchi S; Day NK; Kamchaisatian W; Beigier-Pompadre M; Stenger S; Tangsinmankong N; Sleasman JW; Pizzo SV; Cianciolo GJ AIDS Res Ther; 2006 Mar; 3():8. PubMed ID: 16573838 [TBL] [Abstract][Full Text] [Related]
13. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Jenny-Avital ER; Joseph K Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504 [TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. Bonora S; Mondo A; Trentini L; Calcagno A; Lucchini A; Di Perri G J Infect; 2008 Jul; 57(1):78-81. PubMed ID: 18550175 [TBL] [Abstract][Full Text] [Related]
15. Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. Martin A; Cubillos-Ruiz A; Von Groll A; Del Portillo P; Portaels F; Palomino JC J Antimicrob Chemother; 2008 Jan; 61(1):123-7. PubMed ID: 17981833 [TBL] [Abstract][Full Text] [Related]
16. Nevirapine derivatives with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Sriram D; Srichakravarthy N; Bal TR; Yogeeswari P Biomed Pharmacother; 2005 Sep; 59(8):456-9. PubMed ID: 16140495 [TBL] [Abstract][Full Text] [Related]